Abstract
Type 2 inflammation is central to chronic rhinosinusitis with nasal polyps (CRSwNP), but it does not fully explain persistent stromal and vascular remodeling. We asked whether complement, adhesion, stromal, and vascular signals converge across tissue, cellular, and spatial scales. We integrated four bulk-transcriptomic cohorts with a single-cell atlas and GeoMx spatial transcriptomics. Network analysis identified eight contrast-associated hub genes and an ABCC9-ACTA2-GPM6A score that separated study-defined groups across cohorts. Single-cell mapping localized these genes mainly to pericytes, fibroblasts, and endothelial cells, while CellChat linked structural and immune compartments through extracellular-matrix and inflammatory signals. In spatial data, C3-C3AR1 showed closer-than-random proximity after multiple-testing correction, whereas ICAM1-ITGAL/ITGB2 did not. Anatomical-site sensitivity analyses retained all eight hub-gene directions. These findings support CASVR as an association framework linking complement-related signals to structural-vascular compartments and identify C3-C3AR1 for independent mechanistic testing.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The datasets analysed in this study are publicly available in the Gene Expression Omnibus under accession numbers GSE136825, GSE23552, GSE194282, GSE179265, and GSE276503, and in Zenodo at https://doi.org/10.5281/zenodo.13947018. Data needed to evaluate the conclusions are available from these repositories and the accompanying Supplementary Information. Record-level gene-compound associations, displayed network edges, and redocking settings and results are supplied as Supplementary Data 1-3.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets analysed in this study are publicly available in the Gene Expression Omnibus under accession numbers GSE136825, GSE23552, GSE194282, GSE179265, and GSE276503, and in Zenodo at https://doi.org/10.5281/zenodo.13947018. Data needed to evaluate the conclusions are available from these repositories and the accompanying Supplementary Information. Record-level gene-compound associations, displayed network edges, and redocking settings and results are supplied as Supplementary Data 1-3.
https://doi.org/10.5281/zenodo.13947018
https://www.omicsdi.org/dataset/geo/GSE179265
https://www.omicsdi.org/dataset/geo/GSE194282





